Idex (IEX Quick QuoteIEX - Free Report) reported $886.9 million in revenue for the quarter ended March 2026, representing a year-over-year increase of 8.9%. EPS of $2.00 for the same period compares to $1.75 a year ago.

The reported revenue represents a surprise of +6.2% over the Zacks Consensus Estimate of $835.16 million. With the consensus EPS estimate being $1.78, the EPS surprise was +12.68%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Idex performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Net sales - Organic impact - YoY change: 5% versus 0.9% estimated by two analysts on average.
• Net Sales- Fluid & Metering Technologies (FMT): $301.5 million versus $294.98 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +3.8% change.
• Intersegment sales eliminations: $-1.3 million compared to the $-1.92 million average estimate based on three analysts. The reported number represents a change of -35% year over year.
• Net Sales- Fire & Safety/Diversified Products (FSDP): $188.3 million versus $183.77 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +2.2% change.
• Net Sales- Health & Science Technologies (HST): $398.4 million compared to the $375.34 million average estimate based on three analysts. The reported number represents a change of +16.7% year over year.
• Adjusted EBITDA- Fluid & Metering Technologies (FMT): $98.7 million compared to the $92.29 million average estimate based on three analysts.
• Adjusted EBITDA- Corporate: $-30.1 million versus the three-analyst average estimate of $-27.82 million.
• Adjusted EBITDA- Fire & Safety/Diversified Products (FSDP): $55.8 million compared to the $50.52 million average estimate based on three analysts.
• Adjusted EBITDA- Health & Science Technologies (HST): $106 million compared to the $96.02 million average estimate based on three analysts.

View all Key Company Metrics for Idex here>>>

Shares of Idex have returned +8.3% over the past month versus the Zacks S&P 500 composite's +12.2% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.